GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PositiveID Corp (OTCPK:PSID) » Definitions » Net Cash per Share

PositiveID (PositiveID) Net Cash per Share : $-2.23 (As of Mar. 2018)


View and export this data going back to 2007. Start your Free Trial

What is PositiveID Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). PositiveID's Net Cash per Share for the quarter that ended in Mar. 2018 was $-2.23.

The historical rank and industry rank for PositiveID's Net Cash per Share or its related term are showing as below:

PSID's Price-to-Net-Cash is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 7.045
* Ranked among companies with meaningful Price-to-Net-Cash only.

PositiveID Net Cash per Share Historical Data

The historical data trend for PositiveID's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PositiveID Net Cash per Share Chart

PositiveID Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -12,792.13 -31.04

PositiveID Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,199.58 -889.62 -134.74 -31.04 -2.23

Competitive Comparison of PositiveID's Net Cash per Share

For the Diagnostics & Research subindustry, PositiveID's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PositiveID's Price-to-Net-Cash Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, PositiveID's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where PositiveID's Price-to-Net-Cash falls into.



PositiveID Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

PositiveID's Net Cash per Share for the fiscal year that ended in Dec. 2017 is calculated as

Net Cash per Share (A: Dec. 2017 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.181-11.426--0.098)/0.35908
=-31.04

PositiveID's Net Cash per Share for the quarter that ended in Mar. 2018 is calculated as

Net Cash per Share (Q: Mar. 2018 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.049-11.922-0)/5.33325
=-2.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PositiveID  (OTCPK:PSID) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


PositiveID Net Cash per Share Related Terms

Thank you for viewing the detailed overview of PositiveID's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


PositiveID (PositiveID) Business Description

Traded in Other Exchanges
N/A
Address
1690 South Congress Avenue, Suite 201, Delray Beach, FL, USA, 33445
PositiveID Corp is a life science tools and diagnostics company. It specializes in the biological detection and molecular diagnostic systems for homeland defense and the global healthcare market. The business activity of the firm includes the development of microfluidic systems in order to detect biological threats and outbreaks, whether airborne, in a healthcare setting, or at the point of need through its subsidiary. Further, it is also involved in the development of FireflyDX family of products, automated pathogen detection system for rapid diagnostics, both for clinical and point-of-need applications. In addition, it also manufactures specialty technology vehicles focused primarily on mobile laboratory and communications applications. All the activities are carried out through the US.
Executives
Ned L Siegel director 600 WILSHIRE BOULEVARD, LOS ANGELES CA 90017
Michael E Krawitz director 1690 S CONGRESS AVE, STE 201, DELRAY BEACH FL 33445
Barry M Edelstein director 1100 GREEN VALLEY ROAD, BRYN MAWR PA 19010
Scott R Silverman other: Former 10% Owner
Marxe Austin W & Greenhouse David M 10 percent owner C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Weaver Constance K director 2900 ESPERANZA CROSSING, 2ND FLOOR, AUSTIN TX 78758
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105

PositiveID (PositiveID) Headlines

From GuruFocus

PositiveID's Chairman and CEO Addresses Stockholders

By Marketwired Marketwired 04-26-2018